Iterum Therapeutics (ITRM) Competitors $0.95 -0.02 (-1.76%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$0.95 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. ELDN, ENTA, LFVN, ACRS, NVCT, NLTX, MOLN, TIL, BIOA, and CGENShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Eledon Pharmaceuticals (ELDN), Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), Aclaris Therapeutics (ACRS), Nuvectis Pharma (NVCT), Neoleukin Therapeutics (NLTX), Molecular Partners (MOLN), Instil Bio (TIL), BioAge Labs (BIOA), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors Eledon Pharmaceuticals Enanta Pharmaceuticals Lifevantage Aclaris Therapeutics Nuvectis Pharma Neoleukin Therapeutics Molecular Partners Instil Bio BioAge Labs Compugen Eledon Pharmaceuticals (NASDAQ:ELDN) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Is ELDN or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -79.54% -41.62% Iterum Therapeutics N/A N/A -71.37% Which has more volatility & risk, ELDN or ITRM? Eledon Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500. Do analysts prefer ELDN or ITRM? Eledon Pharmaceuticals presently has a consensus price target of $9.00, suggesting a potential upside of 199.50%. Iterum Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 846.37%. Given Iterum Therapeutics' higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ELDN or ITRM? In the previous week, Iterum Therapeutics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Iterum Therapeutics and 1 mentions for Eledon Pharmaceuticals. Iterum Therapeutics' average media sentiment score of 0.14 beat Eledon Pharmaceuticals' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iterum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of ELDN or ITRM? 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, ELDN or ITRM? Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$36.18M-$2.10-1.43Iterum TherapeuticsN/AN/A-$24.77M-$0.99-0.96 SummaryIterum Therapeutics beats Eledon Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.56M$2.72B$5.56B$9.04BDividend YieldN/A1.78%5.24%4.01%P/E Ratio-0.969.2227.6620.25Price / SalesN/A668.89415.10118.18Price / CashN/A158.5936.8958.07Price / Book-6.344.588.035.67Net Income-$24.77M$31.34M$3.18B$249.21M7 Day Performance-5.84%3.25%2.93%3.27%1 Month Performance0.11%7.08%3.75%5.55%1 Year Performance-17.30%0.17%35.16%21.08% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics1.9169 of 5 stars$0.95-1.8%$9.00+846.4%-15.1%$38.56MN/A-0.9610News CoverageELDNEledon Pharmaceuticals2.0147 of 5 stars$2.71+0.7%$9.00+232.1%+22.2%$161.08MN/A-1.2910Positive NewsENTAEnanta Pharmaceuticals4.0922 of 5 stars$7.56+0.8%$18.00+138.1%-40.0%$160.32M$67.64M-1.67160Positive NewsLFVNLifevantage4.1883 of 5 stars$13.08+3.1%$30.50+133.2%+109.1%$159.74M$200.16M18.96260News CoverageACRSAclaris Therapeutics2.4265 of 5 stars$1.42-3.4%$9.71+584.1%+25.7%$159.17M$18.72M-1.02100NVCTNuvectis Pharma2.6575 of 5 stars$7.47-1.1%$17.00+127.6%+24.2%$157.75MN/A-6.618NLTXNeoleukin TherapeuticsN/A$16.16-2.5%N/A-44.2%$151.87MN/A-5.2090High Trading VolumeMOLNMolecular Partners2.9844 of 5 stars$3.79+0.8%$12.00+216.6%-43.8%$151.81M$5.65M-1.97180TILInstil Bio2.7832 of 5 stars$20.83-9.3%$119.00+471.3%+176.2%$150.66MN/A-1.74410News CoverageBIOABioAge LabsN/A$4.13-1.7%N/AN/A$150.57MN/A0.00N/ACGENCompugen1.5703 of 5 stars$1.78+7.2%$4.00+124.7%+6.6%$148.13M$27.86M-11.1370Positive News Related Companies and Tools Related Companies Eledon Pharmaceuticals Alternatives Enanta Pharmaceuticals Alternatives Lifevantage Alternatives Aclaris Therapeutics Alternatives Nuvectis Pharma Alternatives Neoleukin Therapeutics Alternatives Molecular Partners Alternatives Instil Bio Alternatives BioAge Labs Alternatives Compugen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITRM Stock Alerts